文献速递前列腺癌

确定无早期疾病进展的主动监测前列腺癌患者的长期结局:对减缓或停止监测的启示

Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance.
PubMed 文献 · Eur Urol Oncol · 2024-09-27

研究纳入774例连续三次活检为Gleason分级组1、主动监测≥5年无进展且随访≥10年的前列腺癌患者,分析升级及生存结局。15年无升级生存率21%、无主要升级61%、无治疗73%、无转移98%、总生存95%,前列腺癌特异性生存100%。诊断年份、年龄、BMI和活检阳性针数与非主要升级相关,年龄和PSA密度与主要升级相关。

要点

  • 主动监测5年无进展者15年无转移生存率98%、前列腺癌特异性生存100%。
  • 15年无升级生存率21%、无主要升级生存率61%、无治疗生存率73%。
  • 诊断年份、年龄、BMI和活检阳性针数与非主要升级相关。

核心结论

  • 主动监测5年无进展的患者升级率中等、转移率和死亡率低,部分患者可能受益于主动监测方案的去强化。

研究设计与样本

  • 纳入连续三次活检为Gleason分级组1、主动监测≥5年无进展且随访≥10年的前列腺癌患者774例,采用Cox比例风险回归分析升级风险因素。

主要发现

  • 10年、12年、15年无升级生存率分别为56%、45%、21%,无主要升级生存率分别为88%、83%、61%,无治疗生存率分别为86%、83%、73%,无转移生存率分别为99%、99%、98%,总生存率分别为98%、96%、95%。
  • 15年前列腺癌特异性生存率为100%。
  • 多变量分析中,诊断年份、年龄、BMI和活检阳性针数与升级相关(均p<0.01),年龄和PSA密度与主要升级相关。

临床怎么用

  • 本研究支持在该患者人群中继续主动监测,并在部分患者中去强化监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Active surveillance (AS) of prostate cancer (PCa) is the standard of care for low-grade disease, but there is limited guidance on tailoring protocols for stable patients. We investigated long-term outcomes for patients without initial progression and risk factors for upgrade. METHODS: Men on AS with Gleason grade group (GG) 1 PCa on three serial biopsies, ≥5 yr without progression, and ≥10 yr of follow-up were included. Outcomes were upgrade (GG ≥2), major upgrade (GG ≥3), progression to treatment, metastasis, PCa-specific survival, and overall survival. Cox proportional hazards regression models were used to estimate the associations between patient characteristics and risk of upgrade. KEY FINDINGS AND LIMITATIONS: A total of 774 men met the inclusion criteria. At 10, 12, and 15 yr, upgrade-free survival rates were 56%, 45%, and 21%; major upgrade-free survival rates were 88%, 83%, and 61%; treatment-free survival rates were 86%, 83%, and 73%; metastasis-free survival rates were 99%, 99%, and 98%; and overall survival rates were 98%, 96%, and 95%, respectively. PCa-specific survival was 100% at 15 yr. On a multivariable analysis, year of diagnosis, age, body mass index (BMI), and biopsy core positivity were associated with upgrade (all p < 0.01), whereas age and prostate-specific antigen (PSA) density were associated with major upgrade. CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients without progression for 5 yr on AS had modest rates of upgrade and low rates of metastasis, and mortality at 15 yr of follow-up. Year of diagnosis, older age, increased BMI, and increased biopsy core positivity were associated with upgrade, whereas older age and greater PSA density were associated with an increased risk of major upgrade. A subset of these patients may benefit from deintensification of AS protocols. PATIENT SUMMARY: There are little reported data or clinical guidelines for patients with PCa who are stable for many years on active surveillance (AS). We show, in a large cohort, that PCa patients without progression for 5 yr on AS have modest rates of upgrade and very low rates of metastasis, and mortality rates at 15 yr of follow-up, and that older age, increased body mass index, and increased PCa volume are associated with an increased likelihood of future upgrade. This study supports continued AS in this patient population and deintensification in select patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Shee K, Nie J, Cowan JE, et al. Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance. Eur Urol Oncol. 2024. PMID: 39341710. doi:10.1016/j.euo.2024.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。